Enhancing CD19 Chimeric Antigen Receptor T Cells Through Memory-Enriched T Cells

Clin Cancer Res. 2023 Feb 16;29(4):694-696. doi: 10.1158/1078-0432.CCR-22-3232.

Abstract

Chimeric antigen receptor T (CAR-T) cells directed against CD19 have transformed the therapy of relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL). A recent study reports promising activity and safety of CD19 CAR-T cells generated from naïve, stem, and central memory T cells in adults with R/R B-ALL. See related article by Aldoss et al., p. 742.

Publication types

  • Editorial
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Antigens, CD19 / immunology
  • Cell- and Tissue-Based Therapy
  • Humans
  • Immunotherapy, Adoptive
  • Memory T Cells
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma* / genetics
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma* / immunology
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma* / therapy
  • Receptors, Chimeric Antigen* / genetics
  • Receptors, Chimeric Antigen* / immunology

Substances

  • Receptors, Chimeric Antigen
  • Antigens, CD19